Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028

Amgen has scored a win in its bid to defend its key immunology drug Otezla.

The U.S. Court of Appeals for the Federal Circuit backed a 2021 ruling against Novartis' Sandoz and Zydus. That prior ruling found the generics companies' products would infringe three Amgen patents.